Guangdong Hybribio Biotech Co.,Ltd.

Shenzhen Stock Exchange 300639.SZ

Guangdong Hybribio Biotech Co.,Ltd. Operating Income for the year ending December 31, 2023: USD 6.00 M

Guangdong Hybribio Biotech Co.,Ltd. Operating Income is USD 6.00 M for the year ending December 31, 2023, a -98.11% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Guangdong Hybribio Biotech Co.,Ltd. Operating Income for the year ending December 31, 2022 was USD 317.81 M, a 88.06% change year over year.
  • Guangdong Hybribio Biotech Co.,Ltd. Operating Income for the year ending December 31, 2021 was USD 168.99 M, a 135.28% change year over year.
  • Guangdong Hybribio Biotech Co.,Ltd. Operating Income for the year ending December 31, 2020 was USD 71.83 M, a 220.11% change year over year.
  • Guangdong Hybribio Biotech Co.,Ltd. Operating Income for the year ending December 31, 2019 was USD 22.44 M, a 22.46% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
SV Wall Street
Shenzhen Stock Exchange: 300639.SZ

Guangdong Hybribio Biotech Co.,Ltd.

CEO Ms. Jianyu Wang
IPO Date April 13, 2017
Location Hong Kong
Headquarters 50 Bonham Strand
Employees 2,669
Sector Healthcare
Industries
Description

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. Guangdong Hybribio Biotech Co.,Ltd. was founded in 2003 and is based in Sheung Wan, Hong Kong.

Similar companies

002030.SZ

Daan Gene Co., Ltd.

USD 0.73

-4.26%

300244.SZ

Dian Diagnostics Group Co.,Ltd.

USD 1.44

-2.25%

300482.SZ

Guangzhou Wondfo Biotech Co.,Ltd

USD 3.07

0.63%

300406.SZ

Beijing Strong Biotechnologies, Inc.

USD 1.82

0.98%

603882.SS

Guangzhou Kingmed Diagnostics Group Co., Ltd.

USD 3.37

-1.70%

StockViz Staff

February 3, 2025

Any question? Send us an email